New Treatments for Systemic Mastocytosis
Avapritinib is the most significant new FDA-approved treatment for systemic mastocytosis, demonstrating superior efficacy across both indolent and advanced disease subtypes, with improved overall survival compared to prior standard therapies. 1
FDA-Approved Targeted Therapies
Avapritinib (Preferred Agent)
Avapritinib is a potent and selective KIT D816V inhibitor now FDA-approved for both indolent SM (ISM) and all forms of advanced SM (ASM, SM-AHN, MCL). This represents a paradigm shift as it's the first agent approved for ISM with disease-modifying potential. 1
For Indolent SM:
- The PIONEER trial (2024) demonstrated statistically significant symptom reduction in moderate-to-severe ISM patients who failed ≥2 supportive care medications
- 25 mg daily dosing achieved:
- 15.6-point reduction in total symptom score vs 9.2 points with placebo (P=0.003)
- 54% achieved ≥50% decrease in serum tryptase (vs 0% placebo)
- 68% achieved ≥50% reduction in KIT D816V variant allele frequency (vs 6% placebo)
- 53% reduction in bone marrow mast cell burden (vs 23% placebo) 1
For Advanced SM:
EXPLORER trial showed 75% overall response rate across all advanced subtypes:
- ASM: 100% response rate
- SM-AHN: 76% response rate
- MCL: 69% response rate 1
PATHFINDER trial (200 mg starting dose) confirmed 75% ORR with significant reductions in disease burden markers 1
Critically, retrospective comparison data showed avapritinib improved median OS to 49.0 months vs 26.8 months with best available therapy (HR 0.48, P=0.004), and specifically outperformed midostaurin (HR 0.59) and cladribine (HR 0.32) 1
Critical Safety Caveat:
Avapritinib is contraindicated in patients with platelet counts <50 × 10⁹/L due to intracranial bleeding risk. The EXPLORER trial reported 9 cases of ICB (13%), with 7 associated with severe baseline thrombocytopenia, leading to protocol amendments excluding these patients. 1
Midostaurin (Established Option)
Midostaurin remains FDA-approved for advanced SM only (ASM, SM-AHN, MCL), though it has shown efficacy in severe ISM in smaller trials. The pivotal trial showed 60% ORR in advanced disease with median OS of 29 months, but this is now superseded by avapritinib's superior survival data. 1
Investigational Agents in Clinical Trials
Next-Generation KIT Inhibitors
Bezuclastinib and elenestinib are newer, highly selective oral KIT tyrosine kinase inhibitors currently in clinical trials, designed to be more potent than avapritinib with potentially improved tolerability profiles. 2, 3 These represent the cutting edge of targeted therapy development.
Novel Mechanism Approaches (Early Phase)
Several alternative targets are being explored in nonadvanced SM trials:
- Siglec-8 targeting: Demonstrated potential to reduce symptoms and mast cell burden in small cohorts 4
- mTOR inhibitors: Shown symptom reduction potential in limited patient populations 4
- Bruton tyrosine kinase inhibitors: Currently in trials with no published efficacy data yet 4
- Interleukin-6 targeting: Did not demonstrate sufficient benefit to warrant further development 4
Treatment Algorithm by Disease Subtype
For Symptomatic ISM:
- First-line: Optimize supportive care (antihistamines, leukotriene inhibitors, mast cell stabilizers)
- Second-line: If moderate-to-severe symptoms persist despite ≥2 supportive medications AND platelets ≥50 × 10⁹/L → Avapritinib 25 mg daily 1
- Goal: Symptom control and quality of life improvement
For Advanced SM (ASM, SM-AHN, MCL):
- Preferred: Avapritinib 200 mg daily (if platelets ≥50 × 10⁹/L) 1
- Alternative: Midostaurin 100 mg twice daily
- Other options: Cladribine for mast cell debulking; imatinib only for rare KIT D816V-negative cases with specific mutations 1
- Goal: Reverse organ dysfunction, reduce disease burden, prolong survival
For SM-AHN:
Treatment must address both the mast cell component and the associated hematologic neoplasm. Molecular profiling is essential to guide combination strategies. If aggressive AHN (e.g., acute leukemia) is present, allogeneic stem cell transplant should be considered. 5
Key Clinical Pearls
- Molecular profiling is mandatory: Presence of ASXL1, RUNX1, or SRSF2 mutations confers worse prognosis and may influence treatment intensity 1
- Platelet monitoring is critical: Check baseline and serial platelet counts before and during avapritinib therapy
- The NCCN 2024 guidelines now list avapritinib as preferred therapy across all SM subtypes (when platelets permit), reflecting the strength of survival and quality-of-life data 1